Showing 5601-5610 of 7865 results for "".
- Alma Unveils Versatile Aesthetic Workstation and Smart Skin Analysis Systemhttps://practicaldermatology.com/news/alma-unveils-versatile-aesthetic-workstation-and-smart-skin-analysis-system/2463172/Energy-based device manufacturer Alma has introduced Alma Harmony and Alma IQ. Alma Harmony is the latest version of the company's multi-technology aesthetics workstation and is available for sale in the U.S. This system, according to a press release, builds on a 20-year legacy and is FDA
- Benign Nail Condition Linked to Cancer Riskhttps://practicaldermatology.com/news/benign-nail-condition-linked-cancer-risk/2463171/The presence of a benign nail abnormality may lead to the diagnosis of a rare inherited disorder that increases the risk of developing cancerous tumors of the skin, eyes, kidneys and the tissue that lines the chest and abdomen (eg, the mesothelium), according to scientists at the National Institu
- World Congress for Hair Research Convenes in Texashttps://practicaldermatology.com/news/world-congress-hair-research-convenes-texas/2463139/Hundreds of internationally renowned scientists and clinicians interested in hair research gathered in Dallas, Texas, from April 6-9, for the 13th World Congress for Hair Research. Hosted by the American Hair Research Society (AHRS), a member of the International Federation of Hair Res
- Humira Biosimilar Simlandi Now Available in the UShttps://practicaldermatology.com/news/humira-biosimilar-simlandi-now-available-us/2463126/Teva Pharmaceuticals and Alvotech announced the availability of Simlandi (adalimumab-ryvk) injection in the US as an interchangeable biosimilar to Humira. Simlandi is indicated for the treatment of adult plaque psoriasis and adult hidradenitis suppurativa, as well as adult rheumatoid arthritis, j
- Analysis: Scar Reduction Seen with Fractional CO2 and 5-FU Laser Treatmentshttps://practicaldermatology.com/news/analysis-scar-reduction-seen-fractional-co2-and-5-fu-laser-treatments/2463110/Results from a new meta-analysis suggest that fractional carbon dioxide (FCO2) plus 5-fluorouracil (5-FU) laser therapy was effective in treating hypertrophic and keloid scars. Researchers for the analysis included data from 18 studies (N = 550). The team comprehensively search
- Survey Shows Variability in Hyaluronidase Use Among Practitionershttps://practicaldermatology.com/news/survey-shows-variability-hyaluronidase-use-among-practitioners/2463109/New research suggests there are inconsistencies in the use of hyaluronidase (HYAL) for the treatment of adverse events with hyaluronic acid (HA) fillers, suggesting a need for standardized guidelines. "With the growing popularity and administration of HA fillers, there is likely to be a c
- Johnson & Johnson Acquires Proteologix, Maker of Atopic Dermatitis Candidate, for $850 Millionhttps://practicaldermatology.com/news/johnson-johnson-acquires-proteologix-maker-atopic-dermatitis-candidate-850-million/2463090/Johnson & Johnson has entered into a definitive agreement to acquire biotech company Proteologix for $850 million in cash, with potential for an additional milestone payment. Proteologix’s portfolio includes PX128, a bispecific antibody targeting IL-13 plus TSLP, which is ready to ente
- Study: Apremilast Efficacy Shows Efficacy in Psoriasishttps://practicaldermatology.com/news/study-apremilast-efficacy-shows-efficacy-psoriasis/2463053/Results from a recent analysis suggest promise for apremilast, which showed efficacy in the treatment of patients with moderate-to-severe psoriasis. Authors publishing in Acta Dermato-Venereologica focused on the impact on skin lesions, pruritus, and serum cytokine levels. The r
- Consensus Statement Raises Awareness of CTCLhttps://practicaldermatology.com/news/consensus-statement-raises-awareness-ctcl/2463052/Kyowa Kirin, Inc. announced the publication of a patient-focused global consensus statement developed in collaboration with patient advocacy groups, calling on all healthcare authorities, hospitals, and clinicians to undertake 12 specific actions to enhance awareness, diagnosis, care, and support
- LEO Pharma Announces Topline Results of Phase 3 Trial in China for Plaque Psoriasis Treatment Enstilarhttps://practicaldermatology.com/news/leo-pharma-announces-topline-results-phase-3-trial-china-plaque-psoriasis-treatment-enstilar/2463007/LEO Pharma announced results from the Enstilar phase 3 trial in China in adult patients living with stable plaque psoriasis. The trial is a phase 3, randomised, investigator-blind, active controlled, parallel group, multicenter trial comparing the efficacy and safety of once daily Enstila